Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Allison

Showing results (101-110 of 206) with videos related to

Pageof 21
Sort By:
Cancer Research|May 20, 2016
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor RejectionTodd C Metzger, Hua Long, Shobha Potluri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2017
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid MalignanciesIssa F Khouri, Irina Fernandez Curbelo, Francesco Turturro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trialBradley C Carthon, Jedd D Wolchok, Jianda Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell functionPeter E Fecci, Hidenobu Ochiai, Duane A Mitchell, et al.
The Journal of Clinical Investigation|June 16, 2018
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapySangeeta Goswami, Irina Apostolou, Jan Zhang, et al.
Annals of Surgical Oncology|May 18, 2013
Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanomaDavid E Gyorki, Jianda Yuan, Zhenyu Mu, et al.
Immunity|March 31, 2019
Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell StatesSpencer C Wei, Roshan Sharma, Nana-Ama A S Anang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 14, 2012
B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cellsJun Sik Lee, Lisa Scandiuzzi, Anjana Ray, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 16, 2019
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicitiesSalahaldin A Tahir, Jianjun Gao, Yuji Miura, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 25, 2017
Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor ImmunityMaher G Nawaf, Maria H Ulvmar, David R Withers, et al.
Pageof 21

Showing results (101-110 of 206) with videos related to

Sort By:
Pageof 21
Cancer Research|May 20, 2016
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor RejectionTodd C Metzger, Hua Long, Shobha Potluri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2017
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid MalignanciesIssa F Khouri, Irina Fernandez Curbelo, Francesco Turturro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trialBradley C Carthon, Jedd D Wolchok, Jianda Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell functionPeter E Fecci, Hidenobu Ochiai, Duane A Mitchell, et al.
The Journal of Clinical Investigation|June 16, 2018
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapySangeeta Goswami, Irina Apostolou, Jan Zhang, et al.
Annals of Surgical Oncology|May 18, 2013
Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanomaDavid E Gyorki, Jianda Yuan, Zhenyu Mu, et al.
Immunity|March 31, 2019
Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell StatesSpencer C Wei, Roshan Sharma, Nana-Ama A S Anang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 14, 2012
B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cellsJun Sik Lee, Lisa Scandiuzzi, Anjana Ray, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 16, 2019
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicitiesSalahaldin A Tahir, Jianjun Gao, Yuji Miura, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 25, 2017
Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor ImmunityMaher G Nawaf, Maria H Ulvmar, David R Withers, et al.
Pageof 21